Umbrella Clinical Trials: The Missing Piece in Scalable Gene Editing
Although CRISPR technologies have transformed our ability to edit genes, translating these advances into scalable therapies remains challenging. Thousands of disease-causing mutations still lack targeted therapies, because current development models cannot scale across variants. The challenge becomes even greater when multiple pathogenic variants exist within the same gene, making a one-disease, one-therapy development model difficult to scale for rare diseases.
At ASGCT 2025, platform-based gene editing was emphasized as a promising approach for therapies that are hard to scale. Rather than rebuilding an entire therapeutic program for every mutation, developers can retain the same core components, such as the delivery system and editing machinery, while modifying only the targeting elements. This creates opportunities to reuse data, streamline development and reduce duplication across programs.
However, platformization alone does not solve the problem. Traditional clinical and regulatory frameworks still evaluate most rare genetic disorders as separate development programs, requiring new studies, submissions and review processes for each therapy.
To fully realize the promise of scalable gene editing, clinical development must evolve alongside the technology itself. Umbrella trials may provide the missing clinical and regulatory framework needed to translate platform-based gene editing into scalable therapeutic pipelines.
Umbrella Trials in Gene Editing
An umbrella trial is a clinical development model that allows multiple variant-specific therapies to be evaluated within a shared clinical and regulatory framework. Rather than creating a separate clinical program for each mutation, developers can group therapies that share the same delivery system, editing machinery and disease endpoint under a single trial structure supported by a single IND application.
In this model, evidence, ranging from safety to manufacturing and analytical data, can be leveraged across multiple variants rather than being generated repeatedly for each mutation. This reduces duplication across development programs and supports a more streamlined path through clinical evaluation.
A key advantage of umbrella trials is their adaptability. As new disease-causing variants are identified, they may be added to an existing clinical framework through protocol amendments rather than entirely new development programs. At ASGCT 2026, Prof. Kiran Musunuru described a model for incorporating such variants based primarily on cellular validation data, reducing the need for additional animal studies.
“Could we amend the IND to add a variant and be able to treat the patient with a personalized version of the drug product, not a pre-existing variant? And could we do it based on cellular data alone, with on-target screening and off-target assessment in cells, without having to do any more animal work or toxicology studies, since we are using the same drug?”
By shifting from isolated development programs to a shared, adaptive clinical framework, umbrella trials provide a mechanism for efficiently and continuously scaling gene editing therapies across rare disease populations.
Why Traditional Trial Models Do Not Scale for Gene Editing
Traditional clinical trial models were not designed for variant-specific gene editing. In the conventional pathway, each therapy progresses through Phase I and II studies under relatively flexible early-stage standards, followed by larger and significantly more expensive Phase III trials. Only after this process is completed can a biologics license application (BLA) be submitted, which is required for regulatory approval and reimbursement.
This model becomes increasingly difficult to sustain in ultra-rare genetic diseases. For conditions such as urea cycle disorders, the same development sequence would need to be repeated independently for each gene and each pathogenic variant. At scale, this creates a highly fragmented and resource-intensive pipeline, which helps explain why many ultra-rare diseases still lack approved therapies.
Even as regulatory concepts, such as the FDA’s “plausible mechanism framework” for individualized genetic therapies, the operational requirements remain significant. Sponsors are still expected to establish validated cGMP manufacturing systems, defined process validation plans and robust analytical methods before clinical dosing. For smaller academic or early-stage programs, these requirements can quickly become a limiting factor.
The result is a structural tension: while the science of gene editing is increasingly modular and repeatable, the traditional clinical trial model remains linear, sequential and costly.
“In the traditional way of doing things, we’d enroll subjects with the first disease, variant one, in Phase I/II… and then move to Phase III… We’d finally get to a BLA and get approval. But we’d have to do this repeatedly for all variants, which is why we don’t have many therapies for ultra-rare diseases.”
How Umbrella Trials Enable Variant-Specific Therapies at Scale
Umbrella trials shift clinical development from a serial to a parallel model. Instead of treating each variant-specific therapy as an independent project, they create a single, evolving program that supports multiple therapies simultaneously. This approach is particularly relevant for gene editing platforms, where therapies often share the same delivery systems, editing machinery, manufacturing processes and clinical endpoints.
By operating within a shared framework, umbrella trials allow evidence generated for one therapy to inform the development of others. Rather than rebuilding an entire evidence package for each new variant, developers can leverage existing safety, manufacturing, biodistribution and analytical data. This creates opportunities to expand development programs more efficiently while maintaining regulatory rigor.
Umbrella trials also support a more adaptive approach to clinical development. Therapies may enter an initial proof-of-concept phase to establish early evidence of efficacy, with only the most promising candidates advancing to a validation phase that requires more stringent clinical and CMC standards.
“The answer is an adaptive real-time clinical trial design… Think of a proof-of-concept phase and a validation phase… Once we have persuasive evidence, we advance… If we’re unable to show efficacy, it doesn’t advance.”
This adaptive model aligns closely with the FDA’s emerging plausible mechanism framework. As evidence accumulates across an umbrella trial, early data, including safety findings, manufacturing experience and process validation insights, can help support subsequent programs. The result is a learning system that can use limited patient populations more efficiently and distribute development resources across a larger number of rare disease variants.
“Any data from the first set of therapies… can be applied to subsequent therapies… so development of therapies for all mutations within the same disease can proceed in parallel.”
The New Clinical Paradigm: 'From N-of-1 to N-of-Many.'
The combination of platform-based gene editing technologies and umbrella clinical trial designs is reshaping the operating model of drug development.
CRISPR-based platforms function as reusable systems in which core components remain constant, while modular elements, such as guide RNAs, are varied to target specific mutations. Umbrella trials provide the clinical operating framework for evaluating therapies within a single, coordinated structure, supporting a shift from N-of-1 to N-of-many development.
Rather than building fully independent programs for each mutation, therapies can be developed within standardized, reusable systems supported by shared clinical, manufacturing and regulatory infrastructure. This allows new therapies to be integrated into existing platforms rather than requiring entirely new development pathways.
From Regulation to QC: What Needs to Evolve
While regulatory agencies such as the FDA are increasingly open to platform-based gene therapies, current frameworks still largely default to a one-therapy, one-approval pathway. Even with emerging flexibility, evaluation remains largely structured around gene- or variant-level submissions.
As a result, regulatory systems will need to evolve clearer mechanisms for platform-based development, including recognition of shared evidence across variants and more explicit pathways for adaptive clinical protocols.
At the same time, as manufacturing becomes more standardized through automation, quality control and analytics are emerging as the primary bottlenecks. Regulatory expectations continue to emphasize robust analytical validation as a prerequisite for accepting platform-level evidence, underscoring the need for near-real-time QC systems and standardized analytical frameworks across therapies.
Data fragmentation across discovery, manufacturing and clinical development remains another key challenge. To support a true N-of-many model, these systems must become interoperable, with continuous workflows and integrated infrastructure that allow information to move seamlessly across the development lifecycle.
Ultimately, the next phase of scalable gene editing will depend less on advances in editing technology itself and more on the maturation of regulatory, analytical and data systems capable of supporting platform-based development at scale.
Access the on-demand webinar to explore how scalable CRISPR platforms and adaptive clinical trial designs are reshaping the development of rare diseases.